Stockscreener 앱 받기
14.38
2.79%
0.39
시간 외 거래:
14.39
0.010
+0.07%
전일 마감가:
$13.99
열려 있는:
$14.16
하루 거래량:
2.18M
Relative Volume:
0.86
시가총액:
$11.97B
수익:
$3.81B
순이익/손실:
$485.75M
주가수익비율:
24.48
EPS:
0.5873
순현금흐름:
$175.50M
1주 성능:
-5.70%
1개월 성능:
+10.36%
6개월 성능:
+3.75%
1년 성능:
-3.36%
1일 변동 폭
$14.16
$14.48
1주일 범위
$13.95
$15.67
52주 변동 폭
$12.19
$15.67
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
명칭
Dr Reddys Laboratories Ltd Adr
전화
-
주소
-
Compare RDY vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
14.38 | 12.07B | 3.81B | 485.75M | 175.50M | 0.5873 |
TAK
Takeda Pharmaceutical Co Adr
|
16.77 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.82 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.64 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
74.80 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
555.91 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-12-19 | 다운그레이드 | Nomura | Buy → Neutral |
| 2024-01-11 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2023-08-29 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-05-18 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-30 | 개시 | JP Morgan | Underweight |
| 2022-11-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | 재개 | BofA Securities | Neutral |
| 2021-07-27 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-09-18 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-09-18 | 업그레이드 | Investec | Sell → Hold |
| 2020-01-28 | 다운그레이드 | CLSA | Buy → Outperform |
| 2020-01-27 | 다운그레이드 | CLSA | Buy → Outperform |
| 2020-01-09 | 업그레이드 | Citigroup | Sell → Buy |
| 2019-11-04 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | 업그레이드 | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | 업그레이드 | Macquarie | Neutral → Outperform |
| 2019-06-20 | 개시 | Deutsche Bank | Hold |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-20 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | 업그레이드 | CLSA | Outperform → Buy |
| 2019-01-17 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2017-09-21 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | 업그레이드 | CLSA | Underperform → Outperform |
| 2017-07-28 | 다운그레이드 | CLSA | Underperform → Sell |
| 2016-07-27 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2016-07-27 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2016-02-10 | 업그레이드 | Credit Agricole | Underperform → Buy |
| 2015-11-10 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
Dr Reddys Laboratories Ltd Adr 주식(RDY)의 최신 뉴스
Eli Lilly Upgraded, Carvana Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dr. Reddy’s Laboratories files FY26 annual report with US SEC - scanx.trade
RDDA Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Enterprise value to EBITDA forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Dr. Reddy's Labs ADR files Form 20-F, shares stay tied to US pharma peers - AD HOC NEWS
Enterprise value to EBIT forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR - TradingView
Dr. Reddy’s files 2026 annual report with the SEC - Stock Titan
659157 Forecast — Price Target — Prediction for 2027 - TradingView
Form 6K DR REDDYS LABORATORIES LTD For: 22 June By Investing.com - Investing.com Nigeria
Form 6K Kinross Gold Corp For: 22 June By Investing.com - Investing.com Nigeria
Dr. Reddy’s (NYSE: RDY) allots 6,730 ESOP shares to employees - Stock Titan
Why Dr. Reddy's Venlafaxine XR capsules quietly matter for everyday patients - AD HOC NEWS
Why Dr. Reddy’s Celevida Maxx matters for Indian diabetics - AD HOC NEWS
RDY News | DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - ChartMill
Dr. Reddy's Labs (ADR) Stock (US2565981035): Earnings and valuation keep the ADR in focus - AD HOC NEWS
Dr. Reddy's Laboratories Ltd Stock (INE089A01023): U.S. Bosutinib Launch And Pre-market Drop Put ADR - Ad-hoc-news.de
Dr. Reddy's Laboratories stock (INE089A01023): focus on recent FDA progress and US generics growth - AD HOC NEWS
[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.
With Lenalidomide Headwinds Behind, Dr. Reddy's Turns to Biosimilars and Consumer Health for Growth - Morningstar
Dr. Reddy’s (NYSE: RDY) allots 12,100 ESOP shares, updates capital - Stock Titan
Dr. Reddy’s Laboratories issues 12,100 equity shares under stock options scheme - Business Upturn
Topicus submits revised $2.00 per share proposal for ReadyTech - Investing.com UK
Topicus submits revised $2.00 per share proposal for ReadyTech By Investing.com - Investing.com India
Dr. Reddy's Laboratories Ltd ADR (RDY-N) Stock Price and News - The Globe and Mail
Generic Ozempic to hit pharmacies this week, but availability will vary across Canada - The Globe and Mail
Earnings call transcript: Dr. Reddy’s Q4 2026 misses earnings expectations - Investing.com UK
Earnings call transcript: Dr. Reddy’s Q4 2026 misses earnings expectations By Investing.com - Investing.com India
Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push - Sahm
Dr. Reddy's Laboratories Ltd stock (INE089A01023): earnings miss and dual-market focus draw attentio - AD HOC NEWS
Dr. Reddy's Laboratories stock: Earnings miss shapes outlook - Ad-hoc-news.de
8 Stocks To Buy For Long Term: Analysts recommend 3 largecap, 3 midcap, 2 smallcap scrips; Dr Reddy's Labs on the list - Zee Business
Dr. Reddy’s Labs ADR earnings missed by $0.05, revenue fell short of estimates - Investing.com India
Kotak maintains Reduce rating on Dr. Reddy’s stock on margin miss By Investing.com - Investing.com Nigeria
Dr. Reddy's Earnings: Lenalidomide's Slide Digs Into Numbers, but Base Business Remains Solid - Morningstar
Earnings call transcript: Dr. Reddy’s Q4 2026 revenue misses forecast - Investing.com
Earnings call transcript: Dr. Reddy’s Q4 2026 revenue misses forecast By Investing.com - Investing.com Australia
Dr. Reddy's Laboratories Ltd stock (INE089A01023): Board meeting set for Q4 FY26 results - AD HOC NEWS
Dr. Reddy’s (NYSE: RDY) approves new ESOP and ADR stock option grants - Stock Titan
Dr. Reddy's Grants Employee Stock Options, Raising Dilution Concerns - Whalesbook
Dr. Reddy’s Laboratories grants over 1.19 million stock options to employees - Business Upturn
Dr. Reddy’s Laboratories Board Approves New Stock Option Grants for Employees - InvestyWise
RDY Stock Price, Quote & Chart | DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - ChartMill
Dr. Reddy's Laboratories Ltd. Sponsored ADR Trade Ideas — LS:659157 - TradingView
Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada - ChartMill
Earnings BeforeStock ScreenerSnapshot - Finviz
Dr. Reddy's on Pace for Largest Percent Increase Since June 2025 — Data Talk - Morningstar
Dr. Reddy's Labs (ADR) stock (US2565981035): Why Google Discover changes matter more now - AD HOC NEWS
GDR, ADR & IDR Companies Stock Prices | IIFL Capital - India Infoline
Dr Reddys Laboratories Ltd Adr (RDY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.78%
자본화:
|
볼륨(24시간):